<DOC>
	<DOCNO>NCT00982280</DOCNO>
	<brief_summary>The main objective study evaluate effectiveness , tolerability , safety tapentadol hydrochloride prolong release ( PR ) participant suffer severe chronic pain due osteoarthritis knee take WHO Step III analgesic show lack tolerability . This clinical effectiveness trial design establish link anticipated clinical outcome clinical practice mean select measure clinical subject-reported outcome . The trial compare effectiveness previous analgesic treatment ( WHO Step III ) tapentadol hydrochloride PR treatment define period evaluation .</brief_summary>
	<brief_title>Evaluation Effectiveness Tolerability Tapentadol Hydrochloride Subjects With Severe Pain Due Osteoarthritis Taking WHO Step III Analgesics But Showing Lack Tolerability .</brief_title>
	<detailed_description>The trial last 13 week subject include : - One week observation previous analgesic treatment . - Twelve week treatment tapentadol hydrochloride PR .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Participants must sign Informed Consent Form indicate understand purpose procedure require trial willing participate . Participants men nonpregnant , nonlactating woman . Sexually active woman must postmenopausal , surgically sterile , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , double barrier method , contraceptive patch , male partner sterilization ) entry throughout trial . Women childbearing potential must negative pregnancy test screening . Participants must appropriately communicative verbalize differentiate regard location intensity pain . Participants must least 40 year age . Participants must diagnosis osteoarthritis knee base American College Rheumatology ( ACR ) Classification criterion : Knee pain Radiographic osteophytes Knee pain age 40 year Morning stiffness le 30 minute duration Crepitus motion . Participants must pain reference joint present least 3 month . Participant 's pain must require strong analgesic ( define WHO Step III ) judge Investigator Participant must take WHO Step III analgesic daily basis least 2 week prior Screening Visit . Participant must respond WHO Step III analgesic , i.e. , participant must confirm average pain intensity score ( NRS 3 ) small equal 5 point last 3 day prior Screening Visit . Participant must report opioidrelated side effect reason change analgesic Participant must report rate satisfaction previous analgesic regimen exceed `` fair '' subject satisfaction treatment scale ( 5point VRS ) . Presence clinically significant disease laboratory finding Investigator 's opinion may affect efficacy safety assessment . Presence active systemic local infection may , opinion Investigator , affect efficacy , quality life/function safety assessment . History alcohol drug abuse , suspicion thereof Investigator 's judgement . Presence concomitant autoimmune inflammatory condition . Known history laboratory value reflect severe renal impairment . Known history moderately severely impaired hepatic function . History active hepatitis B C within past 3 month history HIV infection . History seizure disorder epilepsy . Any follow within 1 year : mild/moderate traumatic brain injury , stroke , transient ischemic attack , brain neoplasm . Severe traumatic brain injury within 15 year ( consist 1 following : brain contusion , intracranial hematoma , either unconsciousness post traumatic amnesia last 24 h ) residual sequela suggest transient change consciousness . Pregnant breastfeeding . History allergy , hypersensitivity tapentadol hydrochloride excipients , contraindication relate tapentadol hydrochloride include : participant acute severe bronchial asthma hypercapnia . participant suspect paralytic ileus . Employees Investigator trial site , direct involvement trial trial direction Investigator trial site , well family member employee Investigator . Participation another trial concurrently within 4 week prior Screening Visit . Known suspect able comply protocol use investigational medicinal product . Use monoamine oxidase inhibitor within 14 day Screening Visit . Nonstable dose selective serotonin reuptake inhibitor within 30 day Screening Visit ( dose must remain stable trial ) . Osteoarthritis flare state . Use intraarticular injection hyaluronic acid reference joint within 3 month Screening Visit . Presence condition OA reference joint could confound assessment selfevaluation pain , e.g. , anatomical deformity , significant skin condition abscess syndrome widespread pain fibromyalgia . Subjects OA joint reference joint exclude long reference joint source main pain disability . History clinical sign reference joint crystalinduced ( e.g. , gout , pseudogout ) , metabolic , infectious autoimmune disease . Any painful procedure trial ( e.g. , major surgery include reference joint ) may , opinion Investigator , affect efficacy safety assessment . Pending litigation due chronic pain disability .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>pain assessment</keyword>
	<keyword>tapentadol</keyword>
	<keyword>centrally act analgesic</keyword>
</DOC>